News | July 31, 2021
Zydus Cadila receives approval from USFDA for Fulvestrant Injection
The group now has 320 approvals and has so far filed over 400 ANDAs
The group now has 320 approvals and has so far filed over 400 ANDAs
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Sun Pharma has committed Rs. 100 crores towards these initiatives
Subscribe To Our Newsletter & Stay Updated
